PDCD1 and neoplasm: Therefore, the enhanced response to PD-1 blockade in patients supplemented with the live biotherapeutic CBM588 may be supported by the more significant accumulation of immunosuppressive Rorγt+ Treg to the colon, which may contribute to a more immunogenic reprogramming of tumor-draining lymph nodes that are strategically placed to infiltrate the tumor.